Since the first outbreak of Ebola in 1976, the global pharmaceutical industry has invested little in Ebola research. All previous outbreaks have been sporadic, self-limiting and have occurred in poor populations – generating little, if any, commercial appeal for developing treatments. That is now changing.
The current outbreak, which is the worst on record and responsible for at least 4,500 deaths, is generating unprecedented interest among pharmaceutical companies and research institutions.